N-acryloylmorpholine derivatives as keap1 modulators and uses thereof
GEP20267931BActive Publication Date: 2026-08-25VIVIDION THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- GEP20267931P0
- Authority / Receiving Office
- GE · GE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-08-14
- Filing Date
- 2023-09-28
- Publication Date
- 2026-08-25
- Estimated Expiration
- 2043-09-28
Abstract
Compound of Formula (II), (II) wherein the variables are defined. Said compound is used for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art